Niacin: A long history, but a questionable future

Current Opinion in Lipidology

Volumn 24, Issue 6, 2013, Pages 475-479

  Ginsberg, Henry N ^a   Reyes Soffer, Gissette ^a  

^a University College of Physicians and Surgeons ^*  (United States)

Author keywords

AIM HIGH; HPS2 THRIVE; hyperlipidemia; niacin; treatment

Indexed keywords

ANTILIPEMIC AGENT; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 109A; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT PLUS NICOTINIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; FLUSHING; GASTROINTESTINAL SYMPTOM; HIGH RISK PATIENT; HUMAN; MUSCULOSKELETAL DISEASE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SIDE EFFECT; SKIN DEFECT;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; NIACIN;

EID: 84888306164     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000017     Document Type: Review

References (23)

1. Carlson LA. Nicotinic acid: The broad-spectrum lipid drug. A 50th anniversary review. J Int Med 2005; 258:94-114.
2. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. J Am Med Assoc 1975; 231:360-381.
3. Canner PL, Berge KG, Wenger NK, et al. Fifteen-year mortality in coronary drug project patients: Long-term benefit with niacin. J Am Coll Cardiol 1986; 8:1254-1255.
4. Blankenhorn DH, Nessim SA, Johnson RL, et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. J Am Med Assoc 1987; 257:3233-3240.
5. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323:1289-1298.
6. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidants vitamins or the combination for the prevention of coronary disease. N Engl J Med 2001; 345:1583-1592.
7. Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER 2): A doubleblind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004; 110:3512-3517.
8. Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009; 361:2113-2122.
9. Kamanna VS, Ganji SH, Kashyap ML. Recent advances in niacin and lipid metabolism. Curr Opin Lipidol 2013; 24:239-245.
10. Tunaru S, Kero J, Schaub A, et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its antilipolytic effect. Nat Med 2003; 9: 352-355.
11. Wise A, Foord SM, Fraser NJ, et al. Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem 2003; 278:9869-9874.
12. Lauring B, Taggart AK, Tata JR, et al. Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression. Sci Transl Med 2012; 4:1-10. Preclinical and clinical studies on the role of a putative niacin receptor, GPR109A, demonstrated that the receptor was necessary for the fall in fatty acids and flushing. However, the lipid-altering effects of niacin appeared to be independent of interactions between niacin and GPR109A.
13. Usman MH, Qamar A, Gadi R, et al. Extended-release niacin acutely suppresses postprandial triglyceridemia. Am J Med 2012; 125:1026-1035. A single dose of intermediate-release niacin given just prior to an oral fat-load reduced postprandial triglyceride levels significantly in Whites but not in Blacks. Fatty acids fell acutely after ingestion of niacin and then rebounded later, and the mean fall over the course of the postprandial period correlated with reductions in postprandial triglyceride levels. Blacks had no overall reduction in either fatty acids or postprandial triglyceride levels
14. Investigators AIM-HIGH, Boden WE, Probstfield JL, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365:2255-2267
15. Wright RS. Recent clinical trials evaluating benefit of drug therapy for modification of HDL cholesterol. Curr Opin Cardiol 2013; 28:389-398.
16. Michos ED, Sibley CT, Baer JT, et al. Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: Reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial with previous surrogate endpoint trials. J Am Coll Cardiol 2012; 59:2058-2064.
17. Voight BF, Peloso GM, Kathiresan S. Plasma HDL cholesterol and risk of myocardial infarction: A Mendelian randomisation study. Lancet 2012; 380:572-580.
18. Collaborative Group HPS2-THRIVE. HPS2-Thrive randomized placebocontrolled trial in 25,673 high-risk patients on ER niacin/laropiprant; trial design, prespecified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013; 34:1279-1291
19. Yvan-Charvet L, Kling J, Pagler T, et al. Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler Thromb Vasc Biol 2010; 30:1430-1438.
20. Zhao XQ, Morse JS, Dowdy AA, et al. Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol: The HDL Atherosclerosis Treatment Study. Am J Cardiol 2003; 93:307-312.
21. Kahn SE, Beard JC, Schwartz MW, et al. Increased beta-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance. Diabetes 1989; 38:562-568.
22. Ginsberg HN, Elam M, Lovato L, et al., ACCORD Study Group. for the ACCORD Study Group. Effects of combination lipid therapy on cardiovascular events in type 2 diabetes mellitus: The action to control cardiovascular risk in Diabetes Study Group. N Engl J Med 2010; 362:1563-1574.
23. Kane JP, Malloy MJ, Ports TA, et al. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. J Am Med Assoc 1990; 264:3007-3012. 480-486